SCHEMBL823669

SCHEMBL823669

CCOc1nc(N)nc2ccc(-c3cccc(NS(=O)(=O)c4cn(C)cn4)c3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.43
DHFR P00374 1/20 0.42
SCN9A Q15858 1/20 0.41
GLO1 Q04760 1/20 0.41
MAPT P10636 3/20 0.41
HSD17B1 P14061 2/20 0.41
HSD17B2 P37059 2/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
TP53 P04637 2/20 0.40
MET P08581 1/20 0.40
PARP1 P09874 1/20 0.39
THRB P10828 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTR6 P50406 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL823663 0.86 DHFR (0.54) DHFRMAPTLMNAPOLBTP53
SCHEMBL823645 0.84 DHFR (0.48) DHFRMAPTLMNAPOLBTP53
SCHEMBL823707 0.83 MAPT (0.51) DHFRMAPTLMNAPOLBTP53
SCHEMBL823634 0.82 KDM1A (0.46) DHFRMAPTLMNAPOLBTP53
SCHEMBL823636 0.80 DHFR (0.45) DHFRMAPTLMNAPOLBTP53
SCHEMBL823659 0.80 DHFR (0.44) DHFRMAPTHSD17B1HSD17B2LMNA
SCHEMBL823710 0.80 NR3C2 (0.48) DHFRMAPTLMNAPOLBTP53
SCHEMBL823668 0.77 MAPT (0.42) DHFRMAPTLMNAPOLBTP53
SCHEMBL823769 0.75 DHFR (0.40) DHFRMAPTLMNAPOLBTP53
SCHEMBL823753 0.75 MAP4K4 (0.48) MAPTLMNAPOLBTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-8143394-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2012-03-27 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC (US) 2009-12-31 US disclosed
WO-2008077649-A1 PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS GILEAD SCIENCES, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324543-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PLPBP SYK 3994/4885DHFR 32/4885SCN9A 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.